Detalhe da pesquisa
1.
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2.
PLoS Pathog
; 19(8): e1011328, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549173
2.
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Pharm Res
; 40(7): 1657-1672, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418671
3.
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
J Pharmacol Exp Ther
; 371(2): 231-241, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31406003
4.
Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication.
J Proteome Res
; 16(4): 1542-1555, 2017 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28317380
5.
The role of immunophilins in viral infection.
Biochim Biophys Acta
; 1850(10): 2103-10, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25445708
6.
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.
Antimicrob Agents Chemother
; 60(1): 693-8, 2016 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26552985
7.
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
Gastroenterology
; 148(2): 403-14.e7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25305505
8.
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
Antimicrob Agents Chemother
; 59(5): 2496-507, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25666154
9.
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.
Antimicrob Agents Chemother
; 58(2): 687-97, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24217696
10.
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Antimicrob Agents Chemother
; 58(6): 3327-34, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687498
11.
Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
PLoS One
; 19(4): e0301711, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573968
12.
Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
PLoS One
; 19(3): e0298211, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427624
13.
Correlation between NS5A dimerization and hepatitis C virus replication.
J Biol Chem
; 287(36): 30861-73, 2012 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22801423
14.
HCV NS5A and IRF9 compete for CypA binding.
J Hepatol
; 58(1): 16-23, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22902549
15.
Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice.
Sci Rep
; 13(1): 4594, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944714
16.
The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity.
bioRxiv
; 2023 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37645728
17.
The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity.
Viruses
; 15(10)2023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37896876
18.
The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
J Hepatol
; 57(1): 47-54, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22425702
19.
PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.
Antimicrob Agents Chemother
; 56(2): 672-81, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22083468
20.
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
Antimicrob Agents Chemother
; 56(7): 3888-97, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22585215